Clinical Trial Update: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial is evaluating oral Nuvisertib (TP-3654) in patients with myelofibrosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Nuvisertib (TP-3654)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: RECRUITING